🇺🇸 Alfacalcidol tablets in United States

15 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Creatinine Increased — 2 reports (13.33%)
  2. Blood Lactate Dehydrogenase Increased — 2 reports (13.33%)
  3. Blood Urea Increased — 2 reports (13.33%)
  4. Protein Total Decreased — 2 reports (13.33%)
  5. Red Blood Cell Count Decreased — 2 reports (13.33%)
  6. Alanine Aminotransferase Increased — 1 report (6.67%)
  7. Aspartate Aminotransferase Increased — 1 report (6.67%)
  8. Atrioventricular Block — 1 report (6.67%)
  9. Blood Alkaline Phosphatase Increased — 1 report (6.67%)
  10. C-Reactive Protein Increased — 1 report (6.67%)

Source database →

Alfacalcidol tablets in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Alfacalcidol tablets approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Alfacalcidol tablets in United States?

Chinese SLE Treatment And Research Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.